Table 2.
Adjusted* odds ratios for the association between M6P/IGF2R genotypes c.5002 and c.910 and risk of esophageal and gastric cancer, by histologic type
| M6P/IGF2R G>A | All participants | White males only | ||||||
|---|---|---|---|---|---|---|---|---|
| rs629849/c.5002 | GG | AG | AA | OR (95% CI) for AA/AG vs GG | GG | AG | AA | OR (95% CI) for AA/AG vs GG |
| n | n | n | n | n | n | |||
| Controls | 150 | 35 | 3 | 1.00 Referent | 122 | 27 | 3 | 1.00 Referent |
| Gastric cardia adenocarcinoma | 39 | 11 | 1 | 1.21 (0.58–2.54) | 33 | 10 | 0 | 1.27 (0.56–2.88) |
| Esophogeal adenocarcinoma | 46 | 6 | 1 | 0.60 (0.25–1.44) | 37 | 6 | 1 | 0.77 (0.31–1.89) |
| Esophageal+gastric cardia adenocarcinomas | 85 | 17 | 2 | 0.88 (0.48–1.63) | 70 | 18 | 1 | 1.00 (0.51–1.94) |
| Squamous cell carcinoma | 13 | 5 | 1 | 1.80 (0.64–5.06) | 9 | 4 | 1 | 2.03 (0.63–6.60) |
| Other Gastric adenocarcinomas | 44 | 10 | 1 | 0.98 (0.46–2.08) | 32 | 8 | 0 | 0.98 (0.41–2.35) |
| M6P/IGF2R C>G | CC | CG | GG | OR (95% CI) for GG/CG vs CC | CC | CG | GG | OR (95% CI) for GG/CG vs CC |
| rs8191754/c.901 | n | n | n | n | n | n | ||
| Controls | 154 | 32 | 5 | 1.00 Referents | 128 | 24 | 3 | 1.00 Referents |
| Gastric cardia adenocarcinoma | 37 | 11 | 3 | 1.58 (0.77–3.22) | 30 | 11 | 2 | 2.07 (0.96–4.50) |
| Esophogeal adenocarcinoma | 39 | 13 | 1 | 1.50 (0.74–3.04) | 32 | 11 | 1 | 1.78 (0.81–3.90) |
| Esophageal + gastric cardia adenocarcinomas | 76 | 24 | 4 | 1.53 (0.87–2.70) | 62 | 22 | 3 | 1.92 (1.03–3.59) |
| Squamous cell carcinoma | 16 | 4 | 0 | 1.06 (0.33–3.36) | 12 | 2 | 0 | 0.74 (0.15–3.54) |
| Other Gastric adenocarcinomas | 39 | 16 | 1 | 1.82 (0.92–3.57) | 26 | 14 | 0 | 2.51 (1.16–5.46) |
*
Adjusted for age, sex and site of recruitment.